{
    "clinical_study": {
        "@rank": "62081", 
        "arm_group": {
            "arm_group_label": "11c-acetate and 18F-FDG, and cardiac MRI", 
            "arm_group_type": "Experimental", 
            "description": "For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed."
        }, 
        "brief_summary": {
            "textblock": "This study is looking at differences in metabolism and functional imaging between pulmonary\n      hypertension subjects with near normal right ventricular function and persistent right\n      ventricular dysfunction. We will also measure right ventricular metabolic and structural\n      changes using serial 11C-acetate and 18F-FDG PET/CT and cardiac MRI as response to treatment\n      with ranolazine. Subjects undergo imaging procedures at week 0 and week 26 (optional for\n      near normal function patients). This is a companion imaging trial for patients who are\n      eligible for the treatment trial entitled \"A randomized, double-blind, placebo controlled,\n      multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary\n      hypertension and right ventricular dysfunction accompanied by a comparative study of\n      cellular metabolism in subjects with pulmonary hypertension with and without right\n      ventricular dysfunction\".  Subjects must enroll in companion treatment protocol to qualify\n      for the imaging protocol."
        }, 
        "brief_title": "11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Participation in the companion treatment protocol \"A randomized, double-blind, placebo\n        controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects\n        with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative\n        study of cellular metabolism in subjects with pulmonary hypertension with and without\n        right ventricular dysfunction\"\n\n        Exclusion Criteria:\n\n          -  Pregnancy or lactation: Women of childbearing potential must have a negative urine or\n             blood pregnancy test on the day of the PET/CT scan.\n\n          -  Anxiety or claustrophobia prohibiting completion of imaging\n\n          -  Inability to tolerate imaging procedures (1 hour MRI, 30 min and 15 min PET)\n\n          -  Moderate to severe chronic renal disease defined as an estimated glomerular\n             filtration rate < 30 ml/min/1.73m2\n\n          -  Implantable cardioverter-defibrillator, Pacemaker, hazardous metallic implants or any\n             other contraindication to MRI.\n\n          -  History of uncontrolled diabetes mellitus with fasting glucose > 150 mg/dL at the\n             treatment protocol screening visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917136", 
            "org_study_id": "817786"
        }, 
        "intervention": [
            {
                "arm_group_label": "11c-acetate and 18F-FDG, and cardiac MRI", 
                "description": "For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate", 
                "intervention_name": "11C-acetate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "11c-acetate and 18F-FDG, and cardiac MRI", 
                "description": "For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG", 
                "intervention_name": "[18F]Fluoro-2-deoxy-2-D-glucose", 
                "intervention_type": "Drug", 
                "other_name": "18F-FDG"
            }, 
            {
                "arm_group_label": "11c-acetate and 18F-FDG, and cardiac MRI", 
                "description": "Cardiac MRI is performed at 6 months to measure any change in struction and function of the treatment groups.", 
                "intervention_name": "Cardiac MRI", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pulmonary hypertension", 
            "right ventricular function", 
            "11C acetate", 
            "FDG", 
            "ranolazine"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "contact": {
                "email": "yuchi.han@uphs.upenn.edu", 
                "last_name": "Yuchi Han, MD"
            }, 
            "contact_backup": {
                "email": "baer2@mail.med.upenn.edu", 
                "last_name": "Amanda Baer, MB, MBA"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "University of Pennsylvania"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI", 
        "overall_contact": {
            "email": "yuchi.han@uphs.upenn.edu", 
            "last_name": "Yuchi Han, MD", 
            "phone": "215-662-2855"
        }, 
        "overall_contact_backup": {
            "email": "baer2@mail.med.upenn.edu", 
            "last_name": "Amanda Baer, MB, MBA"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Yuchi Han, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Compare Myocardial oxygen consumption, FDG uptake, and myocardial perfusion at baseline for subjects with near normal right ventricular function and those with persistent right ventricular dysfunction", 
                "measure": "Myocardial oxygen consumption, FDG uptake, and myocardial perfusion", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Assess change from baseline in Myocardial oxygen consumption and FDG uptake and myocardial perfusion in subjects with persistent right ventricular dysfunction who are treated with ranolazine or placebo", 
                "measure": "Myocardial oxygen consumption and FDG uptake and myocardial perfusion", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917136"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "Yuchi Han", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Using CMR, comparing myocardial structure and function in patients treated with ranolazine or placebo", 
            "measure": "Changes in myocardial structure and function", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cardiovascular Medical Research and Education Fund", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Brigham and Women's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Maryland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Yale University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}